CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Erenumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04098250
NCT04098250Phase 2Completed
CompareCT.gov

A Multidisciplinary Translational Approach to Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache

Mayo Clinic·interventional·Posted Sep 23, 2019·Updated Oct 23, 2025

In Brief

A Phase 2 clinical trial evaluating Erenumab and Placebo for Post-Traumatic Headache. Completed, enrolled 6 participants across 5 sites.

Detailed Summary

This is a United States Department of Defense funded Focused Program study that aims to identify mechanisms and predictors for persistent of post-traumatic headache attributed to mild traumatic brain injury, and identify methods of preventing post-traumatic headache persistence. The objective of the clinical trial component of the Focused Program is to determine whether intervention with erenumab is an effective treatment for PTH attributed to mTBI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-Traumatic Headache
CountriesUnited States
CollaboratorsUniversity of Arizona, Translational Genomics Research Institute, Arizona State University, Phoenix VA Health Care System, United States Department of Defense, Amgen, Georgia Institute of Technology

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 23, 2019
Enrollment StartJan 4, 2021
Primary CompletionJan 10, 2024
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 6.8 years ago

Interventions

Erenumabdrug

a CGRP receptor monoclonal antibody

Placeboother

Placebo